DGL Antibody
Description
Desmosomal Glycoprotein 1 (DGL)
Diacylglycerol Lipase Alpha (DAGLA/DGL-α)
Clinical and Diagnostic Implications
DGL Antibodies in Oncology
Monoclonal antibodies targeting desmosomal proteins like DGL are emerging tools for:
-
Cancer subtyping: Distinguishing epithelial-derived tumors (e.g., carcinomas) from non-epithelial malignancies .
-
Therapeutic monitoring: Potential use in tracking epithelial cancer progression .
DAGLA Antibodies in Neuroscience
DAGLA-targeting antibodies enable:
-
Neuroplasticity studies: Investigating 2-AG’s role in synaptic regulation and anxiety disorders .
-
Inflammatory response profiling: Assessing microglial activation in neurodegenerative diseases .
Comparative Analysis of DGL Antibodies
Challenges and Future Directions
-
Specificity Concerns: Antibodies must distinguish between DGL isoforms and cross-reactive epitopes .
-
Therapeutic Potential: Engineering DGL antibodies for targeted drug delivery or immunotherapy remains under exploration .
-
Standardization: Initiatives like the Antibody Characterization Laboratory (ACL) emphasize rigorous validation to mitigate reproducibility issues .
Product Specs
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
Target Background
- The expression of DAD1, DGL, and other DAD1-LIKE LIPASE (DALL) genes is induced upon wounding. Both DAD1 and DGL require CORONATINE ed COI1 for their expression, suggesting that a molecule other than jasmonic acid (JA) might act as a regulator of COI1. PMID: 24430866
- DGL has been found to be localized in lipid bodies and not in plastids. PMID: 20348210
